Review
. 2019 Sep; 8(10):.
doi: 10.3390/jcm8101547.

Immune Checkpoints as Promising Targets for the Treatment of Idiopathic Pulmonary Fibrosis?

JanWillem Duitman 1 Tom van den Ende 2 C Arnold Spek 3 
Affiliations
  • PMID: 31561518
  •     93 References
  •     14 citations

Abstract

Idiopathic pulmonary fibrosis is a rare, progressive and fatal lung disease which affects approximately 5 million persons worldwide. Although pirfenidone and/or nintedanib treatment improves patients' wellbeing, the prognosis of IPF remains poor with 5-year mortality rates still ranging from 70 to 80%. The promise of the anti-cancer agent nintedanib in IPF, in combination with the recent notion that IPF shares several pathogenic pathways with cancer, raised hope that immune checkpoint inhibitors, the novel revolutionary anticancer agents, could also be the eagerly awaited ground-breaking and unconventional novel treatment modality limiting IPF-related morbidity/mortality. In the current review, we analyse the available literature on immune checkpoint proteins in IPF to explore whether immune checkpoint inhibition may be as promising in IPF as it is in cancer. We conclude that despite several promising papers showing that inhibiting specific immune checkpoint proteins limits pulmonary fibrosis, overall the data seem to argue against a general role of immune checkpoint inhibition in IPF and suggest that only PD-1/PD-L1 inhibition may be beneficial.

Keywords: IPF; PD-L1; idiopathic pulmonary fibrosis; immune checkpoints.

Tim-3 marks human natural killer cell maturation and suppresses cell-mediated cytotoxicity.
Lishomwa C Ndhlovu, Sandra Lopez-Vergès, +7 authors, Lewis L Lanier.
Blood, 2012 Mar 03; 119(16). PMID: 22383801    Free PMC article.
Highly Cited.
CTLA-4-Mediated inhibition of early events of T cell proliferation.
M C Brunner, C A Chambers, +3 authors, J P Allison.
J Immunol, 1999 May 07; 162(10). PMID: 10229815
Highly Cited.
Exploration of a potent PI3 kinase/mTOR inhibitor as a novel anti-fibrotic agent in IPF.
Paul F Mercer, Hannah V Woodcock, +15 authors, Rachel C Chambers.
Thorax, 2016 Apr 23; 71(8). PMID: 27103349    Free PMC article.
Highly Cited.
Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors.
P S Linsley, J L Greene, +3 authors, R Peach.
Immunity, 1994 Dec 01; 1(9). PMID: 7534620
Highly Cited.
Overexpression of TIM-3 in Macrophages Aggravates Pathogenesis of Pulmonary Fibrosis in Mice.
Yu Wang, Qiyuan Kuai, +7 authors, Qun Yu.
Am J Respir Cell Mol Biol, 2019 Jun 05; 61(6). PMID: 31162951
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial.
Roy S Herbst, Paul Baas, +16 authors, Edward B Garon.
Lancet, 2015 Dec 30; 387(10027). PMID: 26712084
Highly Cited.
A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.
Talmadge E King, Williamson Z Bradford, +15 authors, ASCEND Study Group.
N Engl J Med, 2014 May 20; 370(22). PMID: 24836312
Highly Cited.
Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials.
Paul W Noble, Carlo Albera, +14 authors, Talmadge E King.
Eur Respir J, 2015 Dec 10; 47(1). PMID: 26647432    Free PMC article.
Highly Cited.
Dual function of CTLA-4 in regulatory T cells and conventional T cells to prevent multiorgan autoimmunity.
Nitya Jain, Hai Nguyen, Cynthia Chambers, Joonsoo Kang.
Proc Natl Acad Sci U S A, 2010 Jan 19; 107(4). PMID: 20080649    Free PMC article.
Lung Microbiota Contribute to Pulmonary Inflammation and Disease Progression in Pulmonary Fibrosis.
David N O'Dwyer, Shanna L Ashley, +15 authors, Robert P Dickson.
Am J Respir Crit Care Med, 2019 Feb 23; 199(9). PMID: 30789747    Free PMC article.
Highly Cited.
Nivolumab Monotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer.
Scott Gettinger, Naiyer A Rizvi, +13 authors, Matthew D Hellmann.
J Clin Oncol, 2016 Jun 30; 34(25). PMID: 27354485    Free PMC article.
Highly Cited.
Immune checkpoint inhibitor treatment in patients with oncogene- addicted non-small cell lung cancer (NSCLC): summary of a multidisciplinary round-table discussion.
Anna S Berghoff, Beatriz Bellosillo, +8 authors, Christoph C Zielinski.
ESMO Open, 2019 Jul 13; 4(3). PMID: 31297240    Free PMC article.
Review.
Long-term safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis: results from the open-label extension study, INPULSIS-ON.
Bruno Crestani, John T Huggins, +8 authors, Michael Kreuter.
Lancet Respir Med, 2018 Sep 19; 7(1). PMID: 30224318
Highly Cited.
Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells.
Mark J Selby, John J Engelhardt, +4 authors, Alan J Korman.
Cancer Immunol Res, 2014 Apr 30; 1(1). PMID: 24777248
Highly Cited.
Morphologic and molecular study of lung cancers associated with idiopathic pulmonary fibrosis and other pulmonary fibroses.
Alice Guyard, Claire Danel, +8 authors, Aurélie Cazes.
Respir Res, 2017 Jun 18; 18(1). PMID: 28619094    Free PMC article.
Combination therapy: the future of management for idiopathic pulmonary fibrosis?
Wim A Wuyts, Katerina M Antoniou, +9 authors, Athol U Wells.
Lancet Respir Med, 2014 Dec 03; 2(11). PMID: 25439569
Review.
B7-1, B7-2 and class II MHC molecules in idiopathic pulmonary fibrosis and bronchiolitis obliterans-organizing pneumonia.
Y Kaneko, K Kuwano, +3 authors, N Hara.
Eur Respir J, 2000 Mar 04; 15(1). PMID: 10678620
Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes.
Y Agata, A Kawasaki, +4 authors, T Honjo.
Int Immunol, 1996 May 01; 8(5). PMID: 8671665
Highly Cited.
Mesenchymal stem cell treatment for IPF-time for phase 2 trials?
Katerina M Antoniou, Konstantinos Karagiannis, Eliza Tsitoura, Nikos Tzanakis.
Lancet Respir Med, 2017 Jul 01; 5(6). PMID: 28664848
Review.
First-Line Nivolumab Plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as Biomarkers.
Neal Ready, Matthew D Hellmann, +25 authors, Suresh S Ramalingam.
J Clin Oncol, 2019 Feb 21; 37(12). PMID: 30785829    Free PMC article.
Highly Cited.
Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade.
Spencer C Wei, Jacob H Levine, +8 authors, James P Allison.
Cell, 2017 Aug 15; 170(6). PMID: 28803728    Free PMC article.
Highly Cited.
Molecular Mechanisms of Pulmonary Fibrogenesis and Its Progression to Lung Cancer: A Review.
Tomonari Kinoshita, Taichiro Goto.
Int J Mol Sci, 2019 Mar 27; 20(6). PMID: 30909462    Free PMC article.
Review.
Modulating the microbiome to improve therapeutic response in cancer.
Jennifer L McQuade, Carrie R Daniel, Beth A Helmink, Jennifer A Wargo.
Lancet Oncol, 2019 Feb 05; 20(2). PMID: 30712808
Highly Cited. Review.
Lung cancer epidemiology, risk factors, and prevention.
Patricia de Groot, Reginald F Munden.
Radiol Clin North Am, 2012 Sep 15; 50(5). PMID: 22974775
Review.
FoxO3 an important player in fibrogenesis and therapeutic target for idiopathic pulmonary fibrosis.
Hamza M Al-Tamari, Swati Dabral, +10 authors, Soni S Pullamsetti.
EMBO Mol Med, 2017 Dec 09; 10(2). PMID: 29217661    Free PMC article.
Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing.
H F Dvorak.
N Engl J Med, 1986 Dec 25; 315(26). PMID: 3537791
Highly Cited. Review.
U.S. FDA Approval Summary: Nivolumab for Treatment of Unresectable or Metastatic Melanoma Following Progression on Ipilimumab.
Maitreyee Hazarika, Meredith K Chuk, +15 authors, Richard Pazdur.
Clin Cancer Res, 2017 Jan 15; 23(14). PMID: 28087644
[Can nivolumab be used safely in idiopathic pulmonary fibrosis?]
B Duchemann, M Didier, +7 authors, H Nunes.
Rev Mal Respir, 2019 Jan 29; 36(2). PMID: 30686563
CTLA-4 can function as a negative regulator of T cell activation.
T L Walunas, D J Lenschow, +5 authors, J A Bluestone.
Immunity, 1994 Aug 01; 1(5). PMID: 7882171
Highly Cited.
Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation.
G J Freeman, A J Long, +16 authors, T Honjo.
J Exp Med, 2000 Oct 04; 192(7). PMID: 11015443    Free PMC article.
Highly Cited.
Immune Checkpoint Inhibitor Toxicity in 2018.
Douglas B Johnson, Sunandana Chandra, Jeffrey A Sosman.
JAMA, 2018 Oct 05; 320(16). PMID: 30286224
Highly Cited.
Idiopathic pulmonary fibrosis and cancer: do they really look similar?
Carlo Vancheri.
BMC Med, 2015 Sep 25; 13. PMID: 26399408    Free PMC article.
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.
Martin Reck, Delvys Rodríguez-Abreu, +16 authors, KEYNOTE-024 Investigators.
N Engl J Med, 2016 Oct 11; 375(19). PMID: 27718847
Highly Cited.
Upregulation of tumor PD-L1 by neoadjuvant chemoradiotherapy (neoCRT) confers improved survival in patients with lymph node metastasis of locally advanced rectal cancers.
Shu-Fen Chiang, Chih-Yang Huang, +5 authors, K S Clifford Chao.
Cancer Immunol Immunother, 2018 Nov 19; 68(2). PMID: 30448924
First-line treatment for patients with advanced non-small cell lung carcinoma and high PD-L1 expression: pembrolizumab or pembrolizumab plus chemotherapy.
Yixin Zhou, Zuan Lin, +4 authors, Li Zhang.
J Immunother Cancer, 2019 May 06; 7(1). PMID: 31053172    Free PMC article.
Fundamental Mechanisms of Immune Checkpoint Blockade Therapy.
Spencer C Wei, Colm R Duffy, James P Allison.
Cancer Discov, 2018 Aug 18; 8(9). PMID: 30115704
Highly Cited. Review.
CD80 (B7) and CD86 (B70) provide similar costimulatory signals for T cell proliferation, cytokine production, and generation of CTL.
L L Lanier, S O'Fallon, +5 authors, M Azuma.
J Immunol, 1995 Jan 01; 154(1). PMID: 7527824
Highly Cited.
CTLA-4 control over Foxp3+ regulatory T cell function.
Kajsa Wing, Yasushi Onishi, +5 authors, Shimon Sakaguchi.
Science, 2008 Oct 11; 322(5899). PMID: 18845758
Highly Cited.
Increased expression of epidermal growth factor receptor (EGF-R) in patients with different forms of lung fibrosis.
Argyris Tzouvelekis, Paschalis Ntolios, +12 authors, Demosthenes Bouros.
Biomed Res Int, 2013 Jul 11; 2013. PMID: 23841084    Free PMC article.
Comparison of Biomarker Modalities for Predicting Response to PD-1/PD-L1 Checkpoint Blockade: A Systematic Review and Meta-analysis.
Steve Lu, Julie E Stein, +11 authors, Janis M Taube.
JAMA Oncol, 2019 Jul 19; 5(8). PMID: 31318407    Free PMC article.
Highly Cited.
The Nobel Prize for Medicine awarded for cancer therapy by inhibition of negative immune regulation.
Peter Hokland, Marianne Hokland, Finbarr Cotter.
Br J Haematol, 2018 Nov 30; 183(5). PMID: 30488426
Idiopathic Pulmonary Fibrosis and Lung Cancer: Finding Similarities within Differences.
Paul A Reyfman, Cara J Gottardi.
Am J Respir Cell Mol Biol, 2019 Jun 06; 61(6). PMID: 31167078    Free PMC article.
PD-1/PD-L1 Pathway Mediates the Alleviation of Pulmonary Fibrosis by Human Mesenchymal Stem Cells in Humanized Mice.
Ke Ni, Ming Liu, +8 authors, Wenwei Tu.
Am J Respir Cell Mol Biol, 2017 Dec 09; 58(6). PMID: 29220578
Monitoring immune-checkpoint blockade: response evaluation and biomarker development.
Mizuki Nishino, Nikhil H Ramaiya, Hiroto Hatabu, F Stephen Hodi.
Nat Rev Clin Oncol, 2017 Jun 28; 14(11). PMID: 28653677    Free PMC article.
Highly Cited. Review.
Membrane PD-L1 expression and soluble PD-L1 plasma levels in idiopathic pulmonary fibrosis-a pilot study.
Dragana Jovanovic, Marina Roksandic Milenkovic, +4 authors, Vesna Skodric Trifunovic.
J Thorac Dis, 2019 Feb 13; 10(12). PMID: 30746211    Free PMC article.
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.
Hossein Borghaei, Luis Paz-Ares, +25 authors, Julie R Brahmer.
N Engl J Med, 2015 Sep 29; 373(17). PMID: 26412456    Free PMC article.
Highly Cited.
A Case of a Patient with Idiopathic Pulmonary Fibrosis with Lung Squamous Cell Carcinoma Treated with Nivolumab.
Monica Khunger, Vamsidhar Velcheti.
J Thorac Oncol, 2017 Jun 21; 12(7). PMID: 28629548    Free PMC article.
Characterization of CD28null T cells in idiopathic pulmonary fibrosis.
David M Habiel, Milena S Espindola, +4 authors, Cory M Hogaboam.
Mucosal Immunol, 2018 Oct 14; 12(1). PMID: 30315241    Free PMC article.
Incidence, Prevalence, and Survival of Patients with Idiopathic Pulmonary Fibrosis in the UK.
Helen Strongman, Imran Kausar, Toby M Maher.
Adv Ther, 2018 Apr 13; 35(5). PMID: 29644539    Free PMC article.
Common Pathogenic Mechanisms Between Idiopathic Pulmonary Fibrosis and Lung Cancer.
Argyris Tzouvelekis, Georgia Gomatou, +3 authors, Demosthenes Bouros.
Chest, 2019 May 28; 156(2). PMID: 31125557
Review.
Pembrolizumab in patients with advanced non-small-cell lung cancer (KEYNOTE-001): 3-year results from an open-label, phase 1 study.
Natasha B Leighl, Matthew D Hellmann, +14 authors, Edward B Garon.
Lancet Respir Med, 2019 Mar 17; 7(4). PMID: 30876831
Highly Cited.
Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses.
Manish J Butte, Mary E Keir, +2 authors, Gordon J Freeman.
Immunity, 2007 Jul 17; 27(1). PMID: 17629517    Free PMC article.
Highly Cited.
Current knowledge of Ipilimumab and its use in treating non-small cell lung cancer.
Joseph A Pinto, Luis E Raez, Helena Oliveres, Christian C Rolfo.
Expert Opin Biol Ther, 2019 Apr 20; 19(6). PMID: 31002006
Review.
Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis.
Luca Richeldi, Roland M du Bois, +21 authors, INPULSIS Trial Investigators.
N Engl J Med, 2014 May 20; 370(22). PMID: 24836310
Highly Cited.
Idiopathic pulmonary fibrosis.
Talmadge E King, Annie Pardo, Moisés Selman.
Lancet, 2011 Jul 02; 378(9807). PMID: 21719092
Highly Cited. Review.
Epidemiology and survival of idiopathic pulmonary fibrosis from national data in Canada.
Robert B Hopkins, Natasha Burke, +2 authors, Martin Kolb.
Eur Respir J, 2016 May 28; 48(1). PMID: 27230442
The role of bacteria in the pathogenesis and progression of idiopathic pulmonary fibrosis.
Phillip L Molyneaux, Michael J Cox, +10 authors, Miriam F Moffatt.
Am J Respir Crit Care Med, 2014 Sep 04; 190(8). PMID: 25184687    Free PMC article.
Highly Cited.
Checkpoint blockade immunotherapy reshapes the high-dimensional phenotypic heterogeneity of murine intratumoural neoantigen-specific CD8+ T cells.
M Fehlings, Y Simoni, +7 authors, E W Newell.
Nat Commun, 2017 Sep 17; 8(1). PMID: 28916749    Free PMC article.
FDA Approval Summary: Pembrolizumab for Treatment of Metastatic Non-Small Cell Lung Cancer: First-Line Therapy and Beyond.
Lee Pai-Scherf, Gideon M Blumenthal, +10 authors, Richard Pazdur.
Oncologist, 2017 Aug 25; 22(11). PMID: 28835513    Free PMC article.
Highly Cited.
Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients.
V Gopalakrishnan, C N Spencer, +67 authors, J A Wargo.
Science, 2017 Nov 04; 359(6371). PMID: 29097493    Free PMC article.
Highly Cited.
Immune-Related Adverse Events Associated with Immune Checkpoint Blockade.
Michael A Postow, Robert Sidlow, Matthew D Hellmann.
N Engl J Med, 2018 Jan 11; 378(2). PMID: 29320654
Highly Cited. Review.
Cutting Edge: Anti-TIM-3 Treatment Exacerbates Pulmonary Inflammation and Fibrosis in Mice.
Takuma Isshiki, Hisaya Akiba, +4 authors, Sachiko Miyake.
J Immunol, 2017 Oct 25; 199(11). PMID: 29061768
Epidermal growth factor receptor paracrine upregulation in idiopathic pulmonary fibrosis fibroblasts is blocked by nintedanib.
Gali Epstein Shochet, Elizabetha Brook, +2 authors, David Shitrit.
Am J Physiol Lung Cell Mol Physiol, 2019 Feb 28; 316(6). PMID: 30810067
FcγRs Modulate the Anti-tumor Activity of Antibodies Targeting the PD-1/PD-L1 Axis.
Rony Dahan, Emanuela Sega, +3 authors, Jeffrey V Ravetch.
Cancer Cell, 2015 Sep 17; 28(3). PMID: 26373277
Highly Cited.
PD-1 up-regulation on CD4+ T cells promotes pulmonary fibrosis through STAT3-mediated IL-17A and TGF-β1 production.
Lindsay J Celada, Jonathan A Kropski, +27 authors, Wonder P Drake.
Sci Transl Med, 2018 Sep 28; 10(460). PMID: 30257954    Free PMC article.
Global incidence and mortality of idiopathic pulmonary fibrosis: a systematic review.
John Hutchinson, Andrew Fogarty, Richard Hubbard, Tricia McKeever.
Eur Respir J, 2015 May 16; 46(3). PMID: 25976683
Highly Cited. Systematic Review.
Idiopathic Pulmonary Fibrosis and Lung Cancer: Mechanisms and Molecular Targets.
Beatriz Ballester, Javier Milara, Julio Cortijo.
Int J Mol Sci, 2019 Feb 02; 20(3). PMID: 30704051    Free PMC article.
Highly Cited. Review.
Gene expression profiles distinguish idiopathic pulmonary fibrosis from hypersensitivity pneumonitis.
Moises Selman, Annie Pardo, +6 authors, Albert Zlotnik.
Am J Respir Crit Care Med, 2005 Sep 17; 173(2). PMID: 16166619    Free PMC article.
Highly Cited.
Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2.
Tadashi Yokosuka, Masako Takamatsu, +3 authors, Takashi Saito.
J Exp Med, 2012 May 30; 209(6). PMID: 22641383    Free PMC article.
Highly Cited.
Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma.
Tyler R Simpson, Fubin Li, +11 authors, Sergio A Quezada.
J Exp Med, 2013 Jul 31; 210(9). PMID: 23897981    Free PMC article.
Highly Cited.
Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors.
Bertrand Routy, Emmanuelle Le Chatelier, +45 authors, Laurence Zitvogel.
Science, 2017 Nov 04; 359(6371). PMID: 29097494
Highly Cited.
Mechanisms of Resistance to Immune Checkpoint Blockade: Why Does Checkpoint Inhibitor Immunotherapy Not Work for All Patients?
Charlene M Fares, Eliezer M Van Allen, +2 authors, Siwen Hu-Lieskovan.
Am Soc Clin Oncol Educ Book, 2019 May 18; 39. PMID: 31099674
Highly Cited. Review.
Nivolumab Gets FDA Nod for Bladder Cancer.
Cancer Discov, 2017 Feb 12; 7(4). PMID: 28183696
Durable response to nivolumab in a lung adenocarcinoma patient with idiopathic pulmonary fibrosis.
Maako Ide, Kentaro Tanaka, +5 authors, Isamu Okamoto.
Thorac Cancer, 2018 Aug 29; 9(11). PMID: 30152594    Free PMC article.
Is idiopathic pulmonary fibrosis a cancer-like disease? Transcriptome analysis to fuel the debate.
C Arnold Spek, JanWillem Duitman.
ERJ Open Res, 2019 Feb 07; 5(1). PMID: 30723726    Free PMC article.
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer.
Julie Brahmer, Karen L Reckamp, +22 authors, David R Spigel.
N Engl J Med, 2015 Jun 02; 373(2). PMID: 26028407    Free PMC article.
Highly Cited.
Idiopathic pulmonary fibrosis: a disease with similarities and links to cancer biology.
C Vancheri, M Failla, N Crimi, G Raghu.
Eur Respir J, 2010 Mar 02; 35(3). PMID: 20190329
Highly Cited.
PD-L1 on invasive fibroblasts drives fibrosis in a humanized model of idiopathic pulmonary fibrosis.
Yan Geng, Xue Liu, +14 authors, Paul W Noble.
JCI Insight, 2019 Feb 15; 4(6). PMID: 30763282    Free PMC article.
Pneumonitis in Patients Treated With Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy.
Jarushka Naidoo, Xuan Wang, +26 authors, Matthew D Hellmann.
J Clin Oncol, 2016 Sep 21; 35(7). PMID: 27646942    Free PMC article.
Highly Cited.
Five-Year Overall Survival for Patients With Advanced Non‒Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study.
Edward B Garon, Matthew D Hellmann, +16 authors, Rina Hui.
J Clin Oncol, 2019 Jun 04; 37(28). PMID: 31154919    Free PMC article.
Highly Cited.
FDA Approval Summary: Pembrolizumab for the Treatment of Patients With Metastatic Non-Small Cell Lung Cancer Whose Tumors Express Programmed Death-Ligand 1.
Joohee Sul, Gideon M Blumenthal, +3 authors, Richard Pazdur.
Oncologist, 2016 Mar 31; 21(5). PMID: 27026676    Free PMC article.
Highly Cited.
PD-L1 positivity predicts response.
Peter Sidaway.
Nat Rev Clin Oncol, 2019 Mar 09; 16(6). PMID: 30846861
PD-L2 is a second ligand for PD-1 and inhibits T cell activation.
Y Latchman, C R Wood, +18 authors, G J Freeman.
Nat Immunol, 2001 Feb 27; 2(3). PMID: 11224527
Highly Cited.
CD80 (B7-1) binds both CD28 and CTLA-4 with a low affinity and very fast kinetics.
P A van der Merwe, D L Bodian, +2 authors, S J Davis.
J Exp Med, 1997 Feb 03; 185(3). PMID: 9053440    Free PMC article.
Highly Cited.
Pre-existing pulmonary fibrosis is a risk factor for anti-PD-1-related pneumonitis in patients with non-small cell lung cancer: A retrospective analysis.
Teppei Yamaguchi, Junichi Shimizu, +4 authors, Toyoaki Hida.
Lung Cancer, 2018 Nov 16; 125. PMID: 30429022
Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway.
Vassiliki A Boussiotis.
N Engl J Med, 2016 Nov 03; 375(18). PMID: 27806234    Free PMC article.
Highly Cited. Review.
Organizing Pneumonia after Nivolumab Treatment in a Patient with Pathologically Proven Idiopathic Pulmonary Fibrosis.
Takeru Kashiwada, Yuji Minegishi, +6 authors, Akihiko Gemma.
J Nippon Med Sch, 2019 Mar 29; 86(1). PMID: 30918156
The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy.
Jonathan J Havel, Diego Chowell, Timothy A Chan.
Nat Rev Cancer, 2019 Feb 14; 19(3). PMID: 30755690    Free PMC article.
Highly Cited. Review.
The Oncogene ECT2 Contributes to a Hyperplastic, Proliferative Lung Epithelial Cell Phenotype in Idiopathic Pulmonary Fibrosis.
Henrik M Ulke, Kathrin Mutze, +5 authors, Melanie Königshoff.
Am J Respir Cell Mol Biol, 2019 May 31; 61(6). PMID: 31145635
The rising incidence of idiopathic pulmonary fibrosis in the U.K.
V Navaratnam, K M Fleming, +4 authors, R B Hubbard.
Thorax, 2011 Apr 29; 66(6). PMID: 21525528
Highly Cited.
A pilot trial of nivolumab treatment for advanced non-small cell lung cancer patients with mild idiopathic interstitial pneumonia.
Daichi Fujimoto, Takeshi Morimoto, +7 authors, Keisuke Tomii.
Lung Cancer, 2017 Aug 26; 111. PMID: 28838377
The intestinal microbiota determines the clinical efficacy of immune checkpoint blockers targeting PD-1/PD-L1.
Lisa Derosa, Bertrand Routy, Guido Kroemer, Laurence Zitvogel.
Oncoimmunology, 2018 Jun 07; 7(6). PMID: 29872574    Free PMC article.
Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
J B A G Haanen, F Carbonnel, +5 authors, ESMO Guidelines Committee.
Ann Oncol, 2017 Sep 09; 28(suppl_4). PMID: 28881921
Highly Cited.
[Research Progress in the Pathogenesis of Idiopathic Pulmonary Fibrosis with Lung Cancer].
Chunhui Liu, Yuanbing He.
Zhongguo Fei Ai Za Zhi, 2020 Aug 26; 23(8). PMID: 32838491    Free PMC article.
Safety and effectiveness of pirfenidone combined with carboplatin-based chemotherapy in patients with idiopathic pulmonary fibrosis and non-small cell lung cancer: A retrospective cohort study.
Yuji Yamamoto, Yukihiro Yano, +7 authors, Masahide Mori.
Thorac Cancer, 2020 Sep 29; 11(11). PMID: 32986306    Free PMC article.
U three protein 14a (UTP14A) promotes tumour proliferation and metastasis via the PERK/eIF2a/GRP78 signalling pathway in oesophageal squamous cell carcinoma.
Kun-Kun Li, Cheng-Yi Mao, +4 authors, Xiao-Long Zhao.
J Cancer, 2021 Jan 05; 12(1). PMID: 33391409    Free PMC article.
Immune Stroma in Lung Cancer and Idiopathic Pulmonary Fibrosis: A Common Biologic Landscape?
Sara Lettieri, Tiberio Oggionni, +2 authors, Giulia Maria Stella.
Int J Mol Sci, 2021 Apr 04; 22(6). PMID: 33809111    Free PMC article.
Review.
Regulatory Immune Cells in Idiopathic Pulmonary Fibrosis: Friends or Foes?
Chiel van Geffen, Astrid Deißler, +3 authors, Saeed Kolahian.
Front Immunol, 2021 May 18; 12. PMID: 33995390    Free PMC article.
Review.
Soluble Programmed Death Ligand-1 (sPD-L1): A Pool of Circulating Proteins Implicated in Health and Diseases.
Christian Bailly, Xavier Thuru, Bruno Quesnel.
Cancers (Basel), 2021 Jul 03; 13(12). PMID: 34204509    Free PMC article.
Review.
[A Case Report of Checkpoint Inhibitor Pneumonitis Caused by PD-1
Antibody-Safety and Effectiveness of Pirfenidone].
Haiming Yu, Jinying Li, +3 authors, Xiaotao Zhang.
Zhongguo Fei Ai Za Zhi, 2021 Jun 17; 24(7). PMID: 34134189    Free PMC article.
Review.
Bioinformatic analysis of differentially expressed genes and pathways in idiopathic pulmonary fibrosis.
Nana Li, Lingxiao Qiu, +5 authors, Guojun Zhang.
Ann Transl Med, 2021 Nov 05; 9(18). PMID: 34734011    Free PMC article.
Molecular Mechanisms and Cellular Contribution from Lung Fibrosis to Lung Cancer Development.
Anna Valeria Samarelli, Valentina Masciale, +14 authors, Enrico Clini.
Int J Mol Sci, 2021 Nov 28; 22(22). PMID: 34830058    Free PMC article.
Review.
CD247, a Potential T Cell-Derived Disease Severity and Prognostic Biomarker in Patients With Idiopathic Pulmonary Fibrosis.
Yupeng Li, Shibin Chen, +4 authors, Hong Chen.
Front Immunol, 2021 Dec 10; 12. PMID: 34880861    Free PMC article.
An 8-ferroptosis-related genes signature from Bronchoalveolar Lavage Fluid for prognosis in patients with idiopathic pulmonary fibrosis.
Yaowu He, Yu Shang, +5 authors, Hong Chen.
BMC Pulm Med, 2022 Jan 06; 22(1). PMID: 34983465    Free PMC article.
Tartrate-resistant acid phosphatase 5 promotes pulmonary fibrosis by modulating β-catenin signaling.
Yinan Hu, Qi Wang, +7 authors, Yi Wang.
Nat Commun, 2022 Jan 12; 13(1). PMID: 35013220    Free PMC article.
PD-L1 mediates lung fibroblast to myofibroblast transition through Smad3 and β-catenin signaling pathways.
Xia Guo, Christudas Sunil, +6 authors, Guoqing Qian.
Sci Rep, 2022 Feb 25; 12(1). PMID: 35197539    Free PMC article.
The oncogenic landscape of the idiopathic pulmonary fibrosis: a narrative review.
Giulia Maria Stella, Vito D'Agnano, +10 authors, Andrea Bianco.
Transl Lung Cancer Res, 2022 Apr 12; 11(3). PMID: 35399571    Free PMC article.
Review.